Skip to main content
Log in

Role of exclusive chemotherapy as first line treatment in oligodendroglioma

  • Clinical Patient -Studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose

The optimal therapy of oligodendrogliomas remains uncertain. Although chemosensitive, these tumors are not chemocurable. We investigated whether chemotherapy delays the need for radiation therapy (RT) without decreasing length and quality of survival.

Methods and materials

Among 89 patients treated for oligodendrogliomas at the Centre Léon Bérard of Lyon from 1982 to 1999, 59 patients fitted inclusion criteria, having had centrally reviewed pure oligodendroglioma requiring treatment. According to the WHO’s classification 35 patients had Grade III and 24, Grade II oligodendrogliomas.

Results

According to the intent to treat, patients were retrospectively classified in three groups as exclusive RT (Group 1), radio-chemotherapy (Group 2), or exclusive chemotherapy (Group 3). Median progression-free survival (PFS): was 47 months [95% confidence interval (CI) 39–56], and median overall survival (OS) was 109 months (95% CI 83–134). In univariate analysis, PFS was correlated with frontal location and WHO classification; OS was correlated with frontal location and Post-operative Karnosky performans status both appearing as independent prognostic factors for OS in multivariate analysis. There was no significant difference between the treatment groups with regard to PFS (P = 0.82) and OS (P = 0.64). In the group of patients treated with exclusive chemotherapy the 5-year PFS and OS rates were 44 and 71%, respectively.

Conclusion

Front-line exclusive chemotherapy results in prolonged OS in patients with confirmed pure oligodendroglioma. Whether this strategy improves quality of life remains debatable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Frappaz D, Chinot O, Bataillard A, Ben Hassel M, Capelle L, Chanalet S et al (2003) Summary version of the standards, options and recommendations for the management of adult patients with intracranial glioma (2002). Br J Cancer 89(Suppl 1):S73–S83

    Article  PubMed  Google Scholar 

  2. Andersen AP (1978) Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 17(6):475–484

    PubMed  CAS  Google Scholar 

  3. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R et al (1981) Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47(4):649–652

    Article  PubMed  CAS  Google Scholar 

  4. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, Anderson H, Borgstrom S, Brun A et al (1991) A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 68(1):22–29

    Article  PubMed  CAS  Google Scholar 

  5. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49(3):333–343

    PubMed  CAS  Google Scholar 

  6. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303(23):1323–1329

    Article  PubMed  CAS  Google Scholar 

  7. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71(8):2585–2597

    Article  PubMed  CAS  Google Scholar 

  8. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311):1011–1018

    Article  PubMed  CAS  Google Scholar 

  9. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O et al (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European organization for research and treatment of cancer study 22845 with the medical research council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52(2):316–324

    Article  PubMed  Google Scholar 

  10. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG et al (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European organization for research and treatment of cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36(3):549–556

    Article  PubMed  CAS  Google Scholar 

  11. Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R et al (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a north central cancer treatment group/radiation therapy oncology group/eastern cooperative oncology group study. J Clin Oncol 20(9):2267–2276

    Article  PubMed  CAS  Google Scholar 

  12. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, Nelson DF et al (1997) Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of radiation therapy oncology group 83-02. Int J Radiat Oncol Biol Phys 38(5):911–914

    Article  PubMed  CAS  Google Scholar 

  13. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473–1479

    Article  PubMed  CAS  Google Scholar 

  14. Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18(3):636–645

    PubMed  CAS  Google Scholar 

  15. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J et al (1994) Chemotherapy for anaplastic oligodendroglioma. National cancer institute of Canada clinical trials group. J Clin Oncol 12(10):2013–2021

    PubMed  CAS  Google Scholar 

  16. Cairncross JG (1994) Aggressive oligodendroglioma: a chemosensitive tumor. Recent Results Cancer Res 135:127–133

    PubMed  CAS  Google Scholar 

  17. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X et al (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19(9):2449–2455

    PubMed  CAS  Google Scholar 

  18. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22(15):3133–3138

    Article  PubMed  CAS  Google Scholar 

  19. Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendroglioma responds to chemotherapy. Neurology 46(1):203–207

    PubMed  CAS  Google Scholar 

  20. Paleologos NA, Macdonald DR, Vick NA, Cairncross JG (1999) Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53(5):1141–1143

    PubMed  CAS  Google Scholar 

  21. Soffietti R, Ruda R, Bradac GB, Schiffer D (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43(5):1066–1073

    Article  PubMed  CAS  Google Scholar 

  22. Stege EM, Kros JM, de Bruin HG, Enting RH, van H, I, Looijenga LH et al (2005) Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103(4):802–809

  23. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO et al (2006) Changing paradigms—an update on the multidisciplinary management of malignant glioma. Oncologist 11(2):165–180

    Article  PubMed  CAS  Google Scholar 

  24. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79(2):153–157

    Article  PubMed  CAS  Google Scholar 

  25. Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A et al (2004) Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 63(5):904–906

    PubMed  CAS  Google Scholar 

  26. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24(18):2707–2714

    Article  PubMed  CAS  Google Scholar 

  27. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24(18):2715–2722

    Article  PubMed  CAS  Google Scholar 

  28. Brown PD, Buckner JC, O’Fallon JR, Iturria NL, Brown CA, O’Neill BP et al (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21(13):2519–2524

    Article  PubMed  Google Scholar 

  29. Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH et al (1998) Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC radiotherapy co-operative group. Eur J Cancer 34(12):1902–1909

    Article  PubMed  CAS  Google Scholar 

  30. Torres IJ, Mundt AJ, Sweeney PJ, Llanes-Macy S, Dunaway L, Castillo M et al (2003) A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 60(7):1113–1118

    PubMed  CAS  Google Scholar 

  31. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280

    PubMed  CAS  Google Scholar 

  32. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  33. Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc Ser B 34:187–202

    Google Scholar 

  34. Burger PC (1995) Revising the world health organization (WHO) blue book—’Histological typing of tumours of the central nervous system’. J Neurooncol 24(1):3–7

    Article  PubMed  CAS  Google Scholar 

  35. Hamlat A, Saikali S, Chaperon J, Le Calve M, Gedouin D, Ben Hassel M et al (2005) Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies. Neurosurg Focus 19(5):E15

    PubMed  Google Scholar 

  36. Nijjar TS, Simpson WJ, Gadalla T, McCartney M (1993) Oligodendroglioma. The princess margaret hospital experience (1958–1984). Cancer 71(12):4002–4006

    Article  PubMed  CAS  Google Scholar 

  37. Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo clinic experience. J Neurosurg 76(3):428–434

    PubMed  CAS  Google Scholar 

  38. Hamlat A, Saikali S, Chaperon J, Le Calve M, Gedouin D, Ben Hassel M et al (2005) Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies. Neurosurg Focus 19(5):E15

    Article  PubMed  Google Scholar 

  39. Nijjar TS, Simpson WJ, Gadalla T, McCartney M (1993) Oligodendroglioma. The princess margaret hospital experience (1958–1984). Cancer 71(12):4002–4006

    Article  PubMed  CAS  Google Scholar 

  40. Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo clinic experience. J Neurosurg 76(3):428–434

    PubMed  CAS  Google Scholar 

  41. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D et al (2006) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neurooncology 8(2):183–188

    CAS  Google Scholar 

  42. Nijjar TS, Simpson WJ, Gadalla T, McCartney M (1993) Oligodendroglioma. The princess margaret hospital experience (1958–1984). Cancer 71(12):4002–4006

    Article  PubMed  CAS  Google Scholar 

  43. Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo clinic experience. J Neurosurg 76(3):428–434

    PubMed  CAS  Google Scholar 

  44. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35(6):1018–1034

    Article  PubMed  CAS  Google Scholar 

  45. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567–573

    PubMed  CAS  Google Scholar 

  46. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35(6):1018–1034

    Article  PubMed  CAS  Google Scholar 

  47. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567–573

    PubMed  CAS  Google Scholar 

  48. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35(6):1018–1034

    Article  PubMed  CAS  Google Scholar 

  49. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567–573

    PubMed  CAS  Google Scholar 

  50. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J et al (1994) Chemotherapy for anaplastic oligodendroglioma. National cancer institute of Canada clinical trials group. J Clin Oncol 12(10):2013–2021

    PubMed  CAS  Google Scholar 

  51. Macdonald DR, Gaspar LE, Cairncross JG (1990) Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27(5):573–574

    Article  PubMed  CAS  Google Scholar 

  52. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24(18):2707–2714

    Article  PubMed  CAS  Google Scholar 

  53. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B et al (2004) Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14(2):121–130

    Article  PubMed  CAS  Google Scholar 

  54. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7(4):839–845

    PubMed  CAS  Google Scholar 

  55. Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18(3):636–645

    PubMed  CAS  Google Scholar 

  56. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24(18):2715–2722

    Article  PubMed  CAS  Google Scholar 

  57. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79(2):153–157

    Article  PubMed  CAS  Google Scholar 

  58. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M et al (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European organization for research and treatment of cancer brain tumor group study 26971. J Clin Oncol 21(13):2525–2528

    Article  PubMed  CAS  Google Scholar 

  59. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X et al (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19(9):2449–2455

    PubMed  CAS  Google Scholar 

  60. van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM et al (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC brain tumor group phase II study 26972. Ann Oncol 14(4):599–602

    Article  PubMed  Google Scholar 

  61. van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM et al (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC brain tumor group phase II study 26972. Ann Oncol 14(4):599–602

    Article  PubMed  Google Scholar 

  62. Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A et al (2004) Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 63(5):904–906

    PubMed  CAS  Google Scholar 

  63. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473–2476

    Article  PubMed  CAS  Google Scholar 

  64. Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendroglioma responds to chemotherapy. Neurology 46(1):203–207

    PubMed  CAS  Google Scholar 

  65. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D et al (2006) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neurooncology 8(2):183–188

    CAS  Google Scholar 

  66. Allam A, Radwi A, El Weshi A, Hassounah M (2000) Oligodendroglioma: an analysis of prognostic factors and treatment results. Am J Clin Oncol 23(2):170–175

    Article  PubMed  CAS  Google Scholar 

  67. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567–573

    PubMed  CAS  Google Scholar 

  68. Nijjar TS, Simpson WJ, Gadalla T, McCartney M (1993) Oligodendroglioma. The princess margaret hospital experience (1958–1984). Cancer 71(12):4002–4006

    Article  PubMed  CAS  Google Scholar 

  69. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35(6):1018–1034

    Article  PubMed  CAS  Google Scholar 

  70. Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T et al (1987) Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 67(2):224–230

    Article  PubMed  CAS  Google Scholar 

  71. Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo clinic experience. J Neurosurg 76(3):428–434

    PubMed  CAS  Google Scholar 

  72. Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo clinic experience. J Neurosurg 76(3):428–434

    Article  PubMed  CAS  Google Scholar 

  73. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567–573

    PubMed  CAS  Google Scholar 

  74. Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH (1997) Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 37(2):399–403

    Article  PubMed  CAS  Google Scholar 

  75. Kros JM, Pieterman H, van Eden CG, Avezaat CJ (1994) Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 34(6):959–966

    Article  PubMed  CAS  Google Scholar 

  76. Bullard DE, Rawlings CE III, Phillips B, Cox EB, Schold SC Jr, Burger P et al (1987) Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 60(9):2179–2188

    Article  PubMed  CAS  Google Scholar 

  77. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO et al (2006) Changing paradigms—an update on the multidisciplinary management of malignant glioma. Oncologist 11(2):165–180

    Article  PubMed  CAS  Google Scholar 

  78. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O et al (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European organization for research and treatment of cancer study 22845 with the medical research council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52(2):316–324

    Article  PubMed  Google Scholar 

  79. Sloan JA, Sargent DJ, Lindman J, Allmer C, Vargas-Chanes D, Creagan ET et al (2002) A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. Qual Life Res 11(1):37–45

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We are indebted to the neuro-oncology division of the Oncology Rhône-Alpes Network (ONCORA). Acknowledgement to Rosalyn Vu for Editing of this manuscript. Preliminary results were presented as a poster at the October 2001 meeting of the American Society of Radiotherapy (ASTRO).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marie Pierre Sunyach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sunyach, M.P., Jouvet, A., Perol, D. et al. Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol 85, 319–328 (2007). https://doi.org/10.1007/s11060-007-9422-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-007-9422-3

Keywords

Navigation